Clinical Trial

Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose Metabolism

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 4, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective will be to evaluate the efficacy of GlycoDual in reducing fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG) levels compared to placebo after 90 days of treatment. Secondary objectives are to estimate: * the change of insulin sensitivity (HOMA-IR) * the change of uricemia after 90 days of supplementation compared to placebo. Safety objectives: Collection of the adverse events not related, related or possibly related to the study products.
Trial Details
NCT Number NCT07263802
Lead Sponsor Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (Prediabetes)
Enrollment 90 participants
Start Date 2025-12-01
Primary Completion 2026-01-31 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-12-04